Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens.
Garrido C, Villacian J, Zahonero N, Pattery T, Garcia F, Gutierrez F, Caballero E, Van Houtte M, Soriano V, de Mendoza C; SINRES Group. Garrido C, et al. Among authors: villacian j. Antimicrob Agents Chemother. 2012 Jun;56(6):2873-8. doi: 10.1128/AAC.06170-11. Epub 2012 Mar 26. Antimicrob Agents Chemother. 2012. PMID: 22450969 Free PMC article.
Performance of a population-based HIV-1 tropism phenotypic assay and correlation with V3 genotypic prediction tools in recent HIV-1 seroconverters.
de Mendoza C, Van Baelen K, Poveda E, Rondelez E, Zahonero N, Stuyver L, Garrido C, Villacian J, Soriano V; Spanish HIV Seroconverter Study Group. de Mendoza C, et al. Among authors: villacian j. J Acquir Immune Defic Syndr. 2008 Jul 1;48(3):241-4. doi: 10.1097/QAI.0b013e3181734f0e. J Acquir Immune Defic Syndr. 2008. PMID: 18545159
Development and performance of conventional HIV-1 phenotyping (Antivirogram®) and genotype-based calculated phenotyping assay (virco®TYPE HIV-1) on protease and reverse transcriptase genes to evaluate drug resistance.
Pattery T, Verlinden Y, De Wolf H, Nauwelaers D, Van Baelen K, Van Houtte M, Mc Kenna P, Villacian J. Pattery T, et al. Among authors: villacian j. Intervirology. 2012;55(2):138-46. doi: 10.1159/000332013. Epub 2012 Jan 24. Intervirology. 2012. PMID: 22286884
Assessment of second-line antiretroviral regimens for HIV therapy in Africa.
Paton NI, Kityo C, Hoppe A, Reid A, Kambugu A, Lugemwa A, van Oosterhout JJ, Kiconco M, Siika A, Mwebaze R, Abwola M, Abongomera G, Mweemba A, Alima H, Atwongyeire D, Nyirenda R, Boles J, Thompson J, Tumukunde D, Chidziva E, Mambule I, Arribas JR, Easterbrook PJ, Hakim J, Walker AS, Mugyenyi P; EARNEST Trial Team. Paton NI, et al. N Engl J Med. 2014 Jul 17;371(3):234-47. doi: 10.1056/NEJMoa1311274. N Engl J Med. 2014. PMID: 25014688 Free article. Clinical Trial.
HIV-1 drug-resistance patterns among patients on failing treatment in a large number of European countries.
van de Vijver DA, Wensing AM, Åsjö B, Bruckova M, Jorgensen LB, Camacho R, Horban A, Linka M, Lazanas M, Loveday C, MacRae E, Nielsen C, Paraskevis D, Poljak M, Puchhammer-Stöckl E, Ruiz L, Schmit JC, Stanczak G, Stanojevic M, Vandamme AM, Vercauteren J, Zazzi M, Bacheler L, Lecocq P, Villacian J, Boucher CA. van de Vijver DA, et al. Among authors: villacian j. Acta Dermatovenerol Alp Pannonica Adriat. 2010 Dec;19(4):3-9. Acta Dermatovenerol Alp Pannonica Adriat. 2010. PMID: 21390473 Free article.
30 results